Showing results (211-220 of 660) with videos related to
Sort By:
Pageof 66
Current Oncology (Toronto, Ont.)|April 21, 2022
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC StudyFiona Turkes, Annette Bryant, Ruwaida Begum, et al.Cancers|May 27, 2026
Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre ExperienceKai Tai Derek Yeung, Simon Gomberg, William Hodgson, et al.The British Journal of Radiology|March 4, 2025
Enhancement of colorectal cancer liver metastases with gadoxetate-enhanced MRI at multiple time points is associated with disease-free survival following hepatectomyJoshua Shur, Leila Kafaei, Angela Riddell, et al.Cancers|February 15, 2022
Optimising Multimodality Treatment of Resectable Oesophago-Gastric AdenocarcinomaAli Abdulnabi Suwaidan, Anderley Gordon, Elizabeth Cartwright, et al.The Oncologist|October 23, 2012
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Sarah Barton, Eliza A Hawkes, Andrew Wotherspoon, et al.The Oncologist|June 3, 2011
Targeting angiogenesis in esophagogastric adenocarcinomaAlicia F C Okines, Andrew R Reynolds, David CunninghamTherapeutic Advances in Medical Oncology|December 22, 2018
Immunotherapy and pancreatic cancer: unique challenges and potential opportunitiesKate Young, Daniel J Hughes, David Cunningham, et al.Journal of Geriatric Oncology|September 28, 2013
Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapyLisa Lowry, Paul Smith, David Cunningham, et al.Clinical Colorectal Cancer|February 19, 2008
Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive markerDiletta Bianchini, Akali Jayanth, Yu Jo Chua, et al.Drugs|November 24, 2007
Pharmacotherapy for oesophagogastric cancerChristopher Jackson, Naureen Starling, Yu Jo Chua, et al.Pageof 66